292 related articles for article (PubMed ID: 37026918)
21. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
22. BAG3 as a novel prognostic biomarker in kidney renal clear cell carcinoma correlating with immune infiltrates.
Gong B; Huang Y; Wang Z; Wan B; Zeng Y; Lv C
Eur J Med Res; 2024 Feb; 29(1):93. PubMed ID: 38297320
[TBL] [Abstract][Full Text] [Related]
23. Cuproptosis-related gene
Wang T; Liu Y; Li Q; Luo Y; Liu D; Li B
Front Immunol; 2022; 13():999823. PubMed ID: 36225932
[TBL] [Abstract][Full Text] [Related]
24. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
25. Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma.
Wang B; Song Q; Wei Y; Wu X; Han T; Bu H; Tang S; Qian J; Shao P
Front Immunol; 2022; 13():948042. PubMed ID: 36275737
[TBL] [Abstract][Full Text] [Related]
26. Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma.
Long S; Wang Y; Chen Y; Fang T; Yao Y; Fu K
Biol Direct; 2022 Oct; 17(1):28. PubMed ID: 36209249
[TBL] [Abstract][Full Text] [Related]
27. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
28. Construction of cuproptosis signature based on bioinformatics and experimental validation in clear cell renal cell carcinoma.
Tian X; Zhu S; Liu W; Wu X; Wei G; Zhang J; Anwaier A; Chen C; Ye S; Che X; Xu W; Qu Y; Zhang H; Ye D
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17451-17466. PubMed ID: 37889309
[TBL] [Abstract][Full Text] [Related]
29. Integrative analysis of single-cell and bulk RNA seq to reveal the prognostic model and tumor microenvironment remodeling mechanisms of cuproptosis-related genes in colorectal cancer.
Chu B; Wang Y; Yang J; Dong B
Aging (Albany NY); 2023 Dec; 15(23):14422-14444. PubMed ID: 38078879
[TBL] [Abstract][Full Text] [Related]
30. A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma.
Zhang W; Wang H; Wang W; Xue H; Qiao M; Song L; Wang S; Ren Z; Ma Z
Anal Cell Pathol (Amst); 2022; 2022():4673514. PubMed ID: 36588797
[TBL] [Abstract][Full Text] [Related]
31. A Comprehensive Pan-Cancer Analysis Reveals Cyclin-Dependent Kinase Inhibitor 2A Gene as a Potential Diagnostic and Prognostic Biomarker in Colon Adenocarcinoma.
Salem A; Ahmed S; Khalfallah M; Hamadan N; ElShikh W; Alfaki M
Cureus; 2024 May; 16(5):e60586. PubMed ID: 38894777
[TBL] [Abstract][Full Text] [Related]
32. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
33. CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer.
Cheng T; Wu Y; Liu Z; Yu Y; Sun S; Guo M; Sun B; Huang C
Front Immunol; 2022; 13():970950. PubMed ID: 36052076
[TBL] [Abstract][Full Text] [Related]
34. Pan-cancer analysis of cuproptosis-promoting gene signature from multiple perspectives.
Ma J; Gong B; Zhao Q
Clin Exp Med; 2023 Dec; 23(8):4997-5014. PubMed ID: 37318649
[TBL] [Abstract][Full Text] [Related]
35. Pan-cancer analysis of CDKN2A alterations identifies a subset of gastric cancer with a cold tumor immune microenvironment.
Deng C; Li ZX; Xie CJ; Zhang QL; Hu BS; Wang MD; Mei J; Yang C; Zhong Z; Wang KW
Hum Genomics; 2024 May; 18(1):55. PubMed ID: 38822443
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of the role of cuproptosis-related genes in the prognosis and immune infiltration of adrenocortical Carcinoma.
You Z; He J; Gao Z
Heliyon; 2024 Jan; 10(1):e23661. PubMed ID: 38187219
[TBL] [Abstract][Full Text] [Related]
37. Bioinformatics analysis and experimental validation of cuproptosis-related lncRNA LINC02154 in clear cell renal cell carcinoma.
Shen J; Wang L; Bi J
BMC Cancer; 2023 Feb; 23(1):160. PubMed ID: 36797708
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
[TBL] [Abstract][Full Text] [Related]
39. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
40. A novel cuproptosis pattern and tumor immune microenvironment characterization in urothelial carcinoma of the bladder.
Feng H; Deng Z; Huang Y; Liu Z; Ruan Y; Wang T; Liu J
Front Immunol; 2023; 14():1219209. PubMed ID: 37662947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]